Skip to main content
Journal cover image

Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.

Publication ,  Journal Article
Seamens, A; Nieman, E; Losavio, K; Bradley, B; Nelson, K; Chen, K-H; Chen, S; Arbiser, J; Lawley, LP
Published in: Exp Dermatol
June 2018

Infantile haemangiomas (IHs) with functional or cosmetic concerns necessitate systemic treatment for which propranolol is the preferred treatment. However, the mechanism of action is unknown. Mouse models suggest the angiopoietin-2 (Ang2)/Tie-2 system is implicated. Ang2 can promote endothelial growth or induce apoptosis depending on the presence of vascular endothelial growth factor. This pilot study investigates the saliva Ang2 levels in infants with IH treated with and without systemic propranolol. Patients with clinically confirmed IHs were recruited from an academic paediatric dermatology centre. Treatment was based on clinical evaluation. Saliva samples were collected over 6 months. An enzyme-linked immunosorbent assay determined Ang2 levels. Ang2 levels were detectable in 45% of samples. However, by the late time point, only 28% had detectable levels. There were no changes of Ang2 over time, and there were no differences in Ang2 levels between groups. However, Ang2 levels were correlated with baseline size and changes in size from baseline. Ang2 is detectable in saliva of affected infants, but does not decrease with propranolol treatment. However, Ang2 levels are positively correlated with size and changes in size. Thus, Ang2 is not the primary factor in the mechanism of propranolol resulting in IH reduction.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Exp Dermatol

DOI

EISSN

1600-0625

Publication Date

June 2018

Volume

27

Issue

6

Start / End Page

636 / 640

Location

Denmark

Related Subject Headings

  • Vasodilator Agents
  • Time Factors
  • Saliva
  • Propranolol
  • Pilot Projects
  • Neoplastic Syndromes, Hereditary
  • Male
  • Infant
  • Humans
  • Hemangioma, Capillary
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Seamens, A., Nieman, E., Losavio, K., Bradley, B., Nelson, K., Chen, K.-H., … Lawley, L. P. (2018). Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol. Exp Dermatol, 27(6), 636–640. https://doi.org/10.1111/exd.13510
Seamens, Alexandra, Elizabeth Nieman, Kristen Losavio, Bridget Bradley, Kate Nelson, Kuang-Ho Chen, Suephy Chen, Jack Arbiser, and Leslie P. Lawley. “Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.Exp Dermatol 27, no. 6 (June 2018): 636–40. https://doi.org/10.1111/exd.13510.
Seamens A, Nieman E, Losavio K, Bradley B, Nelson K, Chen K-H, et al. Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol. Exp Dermatol. 2018 Jun;27(6):636–40.
Seamens, Alexandra, et al. “Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.Exp Dermatol, vol. 27, no. 6, June 2018, pp. 636–40. Pubmed, doi:10.1111/exd.13510.
Seamens A, Nieman E, Losavio K, Bradley B, Nelson K, Chen K-H, Chen S, Arbiser J, Lawley LP. Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol. Exp Dermatol. 2018 Jun;27(6):636–640.
Journal cover image

Published In

Exp Dermatol

DOI

EISSN

1600-0625

Publication Date

June 2018

Volume

27

Issue

6

Start / End Page

636 / 640

Location

Denmark

Related Subject Headings

  • Vasodilator Agents
  • Time Factors
  • Saliva
  • Propranolol
  • Pilot Projects
  • Neoplastic Syndromes, Hereditary
  • Male
  • Infant
  • Humans
  • Hemangioma, Capillary